1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.6-FINAL-08Nov2018-wms.pdf.
2. Wedzicha, J.A., et al., Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med, 2016. 374(23): p. 2222-34.
3. Papi, A., et al., Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet, 2018. 391(10125): p. 1076-1084.
4. Rodrigo, G.J., et al., LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis, 2017. 12: p. 907-922.
5. DiSantostefano, R.L., et al., Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study. PLoS One, 2014. 9(5): p. e97149.
6. Singh, S., A.V. Amin, and Y.K. Loke, Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med, 2009. 169(3): p. 219-29.
7. Siddiqui, S.H., et al., Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med, 2015. 192(4): p. 523-5.
8. Yun, J.H., et al., Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol, 2018. 141(6): p. 2037-2047.e10.
9. Pascoe, S., et al., Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med, 2015. 3(6): p. 435-42.
10. Watz, H., et al., Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med, 2016. 4(5): p. 390-8.
11. Bafadhel, M., et al., Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med, 2018. 6(2): p. 117-126.
12. Pavord, I.D., et al., Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax, 2016. 71(2): p. 118-25.
13. Savran, O., et al., COPD patients prescribed inhaled corticosteroid in general practice: Based on disease characteristics according to guidelines? Chron Respir Dis, 2019. 16: p. 1479973119867949.
14. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf.
15. Recommendations on de-escalation of ICS treatment on COPD patients. Available in Danish from: https://www.lungemedicin.dk/fagligt/299-kol-behandling.html.
16. Casanova, C., et al., Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J, 2017. 50(5).
17. Suissa, S., S. Dell'Aniello, and P. Ernst, Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med, 2018. 6(11): p. 855-862.
18. Donaldson, G.C., et al., Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002. 57(10): p. 847-52.